24/7 Market News Snapshot 22 May, 2025 – GRI Bio, Inc. Common Stock (NASDAQ:GRI)

May 22, 2025

DENVER, Colo., 22 May, 2025 (www.247marketnews.com) – (NASDAQ:GRI) are discussed in this article.
GRI Bio, Inc. is currently navigating a challenging market environment, evidenced by its pre-market stock price of $1.271, which represents a notable decline of approximately 7.90% from the previous closing price of $1.380. The trading volume has reached 3.01 million shares, indicating increased market activity that could be driven by various investor sentiments and recent news affecting the stock’s performance. Technical analyses suggest resistance levels near $1.30 and potential support around $1.20. This downward trend may compel investors to carefully monitor trading volumes and market developments for strategic decision-making as volatility persists.

In tandem with its stock market developments, GRI Bio is making significant strides in its pharmacological research. The company recently presented promising preclinical findings for its lead therapeutic candidate, GRI-0621, at the American Thoracic Society (ATS) International Conference. The results showcase GRI-0621’s robust anti-inflammatory and anti-fibrotic properties in the context of idiopathic pulmonary fibrosis (IPF), highlighting the urgent need for effective treatments for this serious condition.

Dr. Marc Hertz, CEO of GRI Bio, emphasized the importance of these findings during his presentation, noting that GRI-0621 successfully inhibits fibroblast activation and fibrosis in a murine model when given post-inflammatory phase. This research underlines the pivotal role of invariant Natural Killer T (iNKT) cells in the development of fibrotic lung diseases.

As part of its ongoing Phase 2a clinical study, GRI-0621 is currently undergoing a 12-week, double-blind, randomized, placebo-controlled trial designed to evaluate both its safety and its influence on biomarkers associated with disease progression. Preliminary safety results are promising, showing that GRI-0621 is well-tolerated without significant adverse effects on lipid profiles among participants. GRI Bio looks forward to sharing top-line data in the upcoming months, reaffirming its dedication to advancing innovative treatments aimed at improving patient outcomes in inflammatory and fibrotic diseases.

Related news for (GRI)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.